VialCJC-1295 (no DAC) + Ipamorelin 20 mg cartridge
Also known as CJC-1295 + IPA
Growth hormone stack
Investigated for dual-pathway growth hormone signaling.
- Ships from Canada in 1–2 business days
- Free shipping over $120
Place your order, then send the e-Transfer. We pack it as soon as it arrives.
For research use only. Not for human consumption.
Complete your setup
A cartridge goes in the reusable pen.
- Reusable Metal Pen
$49.00 · Holds the cartridge · reusable
- Alcohol Wipes
Free · To wipe the pen's rubber seal
About CJC-1295 + Ipamorelin
This combination pairs a GHRH analog with a selective growth-hormone secretagogue, studied for whether engaging two complementary steps in the release cascade differs from either alone.
How it works
- Dual Pathway
- Combines a releasing-hormone analog with a secretagogue, each studied for a distinct step in the release cascade.
- Pulsatile Support
- Explored for whether the pairing preserves the body's natural pulsatile rhythm of secretion.
What you need
- Reusable Metal Pen
- Alcohol Wipes
- A protocol guide comes with every order
Shipping & payment
- Packed and dispatched within 1–2 business days
- Delivered across Canada in 2–5 business days, tracked
- Temperature-controlled packaging where the product needs it
- Free shipping on orders over $120
- Prices in CAD · pay by Interac e-Transfer
- Format
- Single cartridge for the reusable CoreX pen
- Strength
- 20 mg per cartridge
- Storage
- Refrigerate, away from light. Once reconstituted, keep refrigerated and use within the window on the insert.
- Route in research
- Subcutaneous
- Target
- GHRH-R + GHS-R1a
- SKU
- CP20SC
- Purity
- High-performance liquid chromatography (HPLC), by an independent laboratory
- Identity
- Mass spectrometry, on the same batch
- How often
- Every batch
- COA
- The certificate of analysis is matched to the lot code printed on your vial
- Evidence
- Early clinical
Check your lot
Every vial carries a lot code. Enter it, or scan the QR on the label, to see its expiry and certificate of analysis.
Early clinicalCJC-1295 has been evaluated in a randomized controlled trial in healthy adults, and Ipamorelin has been characterized as a selective growth hormone secretagogue, but the combination itself has not been established in large-scale clinical trials and neither component is regulator-approved.
What research examines
- Prolonged GH and IGF-I secretion with CJC-1295 in healthy adults
- Selective GH release via ghrelin-receptor agonism with Ipamorelin
- Combined GHRH-R and GHS-R1a signaling on pituitary GH release
- Preservation of pulsatile GH secretion patterns
- Body composition and lean-mass research contexts
- Recovery and musculoskeletal applications discussed in sports medicine reviews
Reported in studies
- Human safety data for the combination are limited
- Adverse events are not summarized for the blend in the cited studies
- CJC-1295 has been reported to produce prolonged elevation of GH and IGF-I
- Safety of unapproved peptides for athletic performance has been reviewed in sports medicine literature
- Synthetic GHRH analogs are targets of anti-doping detection methods
Published research protocols
500 mcg, 5 days on 2 days off, pre-sleep fasted
Research protocols have used 200–600 mcg per administration, 5 days per week (pre-sleep), in 12-week blocks with 4 weeks off.
For research use only. These figures summarize published research protocols. They are not instructions or medical advice.
Measure with the calculatorCoreX AI
Ask about CJC-1295 + Ipamorelin
Plain answers, from the basics to the studies.
Research information, not medical advice.
Often researched with CJC-1295 + Ipamorelin
Researched for weight & body composition.
Vial
Vial
Vial
FAQ
Questions, answered
CJC-1295 + Ipamorelin, also called CJC-1295 + IPA, is a research blend pairing CJC-1295, a long-acting analog of growth hormone-releasing hormone (GHRH), with Ipamorelin, a selective growth hormone secretagogue. The combination is studied for whether engaging two complementary steps in the growth hormone release cascade differs from using either compound alone. It is supplied for laboratory research use only.
The blend targets two receptor classes. CJC-1295 acts at the GHRH receptor (GHRH-R), the pathway through which releasing hormone signals the pituitary. Ipamorelin acts at the ghrelin receptor (GHS-R1a), a separate route that also stimulates growth hormone release. Research has explored whether this dual-pathway approach supports endogenous hormone release while preserving the natural pulsatile rhythm of secretion, rather than producing a constant signal.
A randomized controlled trial in healthy adults reported that CJC-1295 produced prolonged stimulation of growth hormone and IGF-I secretion. Ipamorelin was described in 1998 as the first selective growth hormone secretagogue. Reviews have discussed growth hormone secretagogues in body composition research, and recent sports medicine and orthopaedic reviews have examined peptides of this type in recovery and musculoskeletal contexts. Evidence for the combination specifically remains limited.
Human safety data for the combination are limited, and adverse events for the blend are not summarized in the cited studies. CJC-1295 has been reported to cause prolonged elevation of GH and IGF-I, which is relevant to monitoring in research settings. Recent reviews have assessed the safety of unapproved peptides used for musculoskeletal injury and athletic performance, and synthetic GHRH analogs are subject to anti-doping detection methods.
Research protocols have used 200–600 mcg per administration by the subcutaneous route, 5 days per week in a pre-sleep timing, arranged in 12-week blocks followed by 4 weeks off. These figures describe what protocols have used and are not recommendations. Each CoreX order ships with a protocol guide for laboratory reference.
You may also like
Vial · Pen
Vial · Pen
Vial
Vial
